The ongoing district court litigation of Amgen v Hospira—a case regarding Hospira’s proposed biosimilar to epoetin alfa (Epogen), a biological agent used to treat anemia—progressed on May 26, 2017, when counsel for Amgen filed a motion for a preliminary injunction.
The ongoing district court litigation of Amgen v Hospira—a case regarding Hospira’s proposed biosimilar to epoetin alfa (Epogen), a biological agent used to treat anemia—progressed on May 26, 2017, when counsel for Amgen filed a motion for a preliminary injunction. As Big Molecule Watch reports, the motion seeks to keep Hospira from launching its new biosimilar until Hospira “has complied with the requirement of 42 U.S.C. § 262(l)(8)(A), which states that ‘[t]he subsection (k) applicant shall provide notice to [Amgen] not later than 180 days before the date of the first commercial marketing of the biological product licensed under subsection (k).’”
Amgen’s motion follows on the heels of an FDA Advisory Committee’s recommendation on May 25, 2017, that the epoetin alfa biosimilar proposed by Pfizer (parent company to Hospira) be approved across all indications. In a press release, Pfizer representatives announced that the FDA’s Oncologic Drugs Advisory Committee had recommended approval of its biosimilar product, marking the first time that a biosimilar erythropoiesis-stimulating agent has been recommended for approval by such a committee.
Amgen v Hospira represents yet another legal battle in the so-called “patent-dance,” and joins the ongoing case of Amgen v Sandoz, which is currently being considered by the Supreme Court of the United States. At issue in Amgen v Sandoz is whether a biosimilar applicant is required by law to provide the reference product’s sponsor with a copy of its biologics license application and manufacturing information, and what recourse the reference product’s manufacturer has should the biosimilar applicant decline to provide those materials.
As Big Molecule Watch also reported, it is Sandoz’s position that, in legislation that stipulates that a biosimilar product manufacturer “shall” provide its application and marketing materials to the reference product’s sponsor, “shall” could be construed to mean that the applicant shall provide those materials only if it wishes to do so. Amgen, for its part, called Sandoz’s position a “surpassingly strange interpretation.”
The Supreme Court heard oral arguments in Amgen v Sandoz on April 26, 2017, and is expected to rule shortly. The Court’s decision in this case will have ripple effects throughout the industry, and may well affect the outcome of such ongoing cases as Amgen v Hospira by providing a clear judicial interpretation of the requirements for pre-marketing notice for biosimilar applicants.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.